MK-0966 Type of group

A Multi-Center, Parallel-Group, Active Comparator-Controlled, 6-Week, Double-Blind Study to Compare the Tolerability Profile of MK-0966 Versus Arthrotec™ as Measured by the Incidence of Selected Spontaneously Reported Adverse Events in Patients With Osteoarthritis

A Multicenter, Randomized, Parallel-Group, Active- and Placebo-Controlled, Double- Blind Study Conducted Under In-House Blinding Conditions to Determine the Incidence of Gastroduodenal Ulcers in Patients With Rheumatoid Arthritis After 12 Weeks of Treatment With MK-0966, Naproxen, or Placebo

AN ACTIVE-COMPARATOR- AND PLACEBO-CONTROLLED, PARALLEL-GROUP, DOUBLE-BLIND, 52-WEEK STUDY TO ASSESS THE SAFETY AND EFFICACY OF MK-0966 IN RHEUMATOID ARTHRITIS PATIENTS